Even though this analysis was preliminary in terms of the number of patients and the potential to improve the sensitivity of the ELISA, it was clearly evident that the soluble EphA2 fragment exists in blood from cancer patients and could be useful as a diagnostic biomarker for detecting pancreatic cancer. Here, EPHA2 is linked to cancer.